Facebook  Twitter  Youtube  ISSUU  RSS  Email

Advanced Search

Advanced Search Results

Search results for diagnosing bribery risk

Jun 2016 | Blog

Corruption within the pharmaceutical and healthcare sectors is a matter of life and death. It has a corrosive impact on health, negatively impacting public health budgets, the price of health services and medicines, and ultimately the quality of care dispensed. Reports estimate that as much as 6% of annual global health expenditure is lost to corruption

Dec 2013 | Page

      Incentivising Ethics: Managing Incentives to Encourage Good and Deter Bad Behaviour (October 2016)               Managing Third Party Risk: Only as Strong as Your Weakest Link (June 2016)               Wise Counsel or Dark Arts? Principles and Guidance for Responsible Corporate Political

Jul 2013 | Publication

Transparency International's guidance provides specific, practical advice based on real-life experience on how to conduct an effective bribery risk assessment.

Jul 2014 | Blog

The Government announced last year that it would publish its first-ever National Anti-Corruption Action Plan. Since TI first proposed this idea five years ago, we have been arguing that the Government should draw up such a plan, and we are delighted that it is now happening.

Jul 2013 | Blog

Robert Barrington and Will Kenyon discuss some of the challenges facing companies and why conducting an effective bribery risk assessment is necessary.

Jul 2013 | Blog

In the past few days, we have seen two high-profile corruption stories emanating from China – the allegations against GlaxoSmithKline (GSK) and the indictment of high-profile regional governor Bo Xilai. What should we make of them?

Contact Us | Sitemap | Privacy

UK Charity Number 1112842

Transparency International UK is a chapter of